Email to a Colleague
Medscape Conference Coverage, based on selected sessions at the:
Fifteenth European Meeting on Hypertension
June 17 - 21, 2005, Milan, Italy

This activity is not sanctioned by, nor a part of, the Fifteenth European Meeting on Hypertension.


Session Coverage
Clinical Outcomes in Patients With Metabolic Syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Three years on, and the ALLHAT results continue to provide new interpretations -- and new controversy.
Cardiovascular Outcomes in High-Risk Patients Randomized to Lisinopril or Amlodipine in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The huge ALLHAT trial continues to be mined for results -- for example, just when, in whom, are ACE inhibitors or calcium antagonists more effective?
Outcomes in Patients Treated With Monotherapy in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial
The VALUE trial results from last year's ESH meeting proved difficult to interpret, and a further interpretation was presented at this year's meeting.
New Evidence of Blood Pressure-Independent Effects for Agents Acting via the Renin-Angiotensin System: Analyses From The Blood Pressure Lowering Treatment Trialists' Collaboration
Are ARBs truly "like ACE inhibitors without the cough," as a recent BMJ article suggested? Not if you review this evidence.
FEVER: Felodipine Event Reduction Study
It is now firmly established that blood pressure must be targeted to < 140/90 mm Hg in patients with diabetes or previous CVD -- but what about other at-risk patients, as in this very large Chinese study?
Diastolic Blood Pressure and Outcome in Isolated Systolic Hypertension
Can blood pressure be so low that it is actually detrimental -- the so-called J-curve? A new analysis of the Syst-Eur results suggests an answer.
Meta-analyses of Cardiovascular Events in Clinical Trials Comparing Antihypertensive Drugs
The question of first-line antihypertensive therapy continues to be debated, and a small meta-analysis has now updated some of the evidence.
PERFECT: Perindopril-Function of the Endothelium in Coronary Artery Disease Trial
The EUROPA trial proved that the ACE inhibitor perindopril lowers risk for events by 20% in low-risk CAD patients -- but why? The substudy PERFECT assessed the ACE inhibitor's effects on the endothelium.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Fifteenth European Meeting on Hypertension. These materials and the related activity are not sanctioned by the Fifteenth European Meeting on Hypertension or the commercial supporter of the conference, and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2005 Medscape.

 
Pfizer
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.